SCHEMBL13624586

SCHEMBL13624586

COc1ccc2c(N)c(C(C)=O)oc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.59
ALDH1A1 P00352 10/20 0.59
SMN1; SMN2 Q16637 6/20 0.59
HPGD P15428 6/20 0.59
HSD17B10 Q99714 5/20 0.59
TP53 P04637 1/20 0.59
HTT P42858 1/20 0.59
NPC1 O15118 7/20 0.57
RAB9A P51151 7/20 0.57
MAPT P10636 5/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 1/20 0.57
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15766209 0.88 KDM4E (0.76) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL13699674 0.88 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL28834775 0.87 KDM4E (0.79) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL18412928 0.78 MAPT (0.49) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL20534963 0.77 KDM4E (0.52) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL1849885 0.76 KDM4E (0.76) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL6243382 0.74 KDM4E (0.73) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL10372134 0.74 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10TP53
SCHEMBL27283285 0.74 KDM4E (0.61) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL4762078 0.74 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622582-B2 Derivatives of 1-phenyl-benzofuro[3,2]pyridin-2(1H)-one TIBOTEC BVBA (BE) 2009-11-24 US disclosed
US-7622582-B2 Derivatives of 1-phenyl-benzofuro[3,2]pyridin-2(1H)-one TIBOTEC BVBA (BE) 2009-11-24 US disclosed
US-20070213320-A1 4-SUBSTITUTED-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES TIBOTEC BVBA (BE) 2007-09-13 US disclosed
US-20070213320-A1 4-SUBSTITUTED-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES TIBOTEC BVBA (BE) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213320-A1 4-SUBSTITUTED-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES NR2C2, CYP4B1, OXER1 KDM4E 3819/4885ALDH1A1 1060/4885SMN1; SMN2 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.